← Leaderboards
Tony P George
Yale University
$3,429,046
Attributed
$3,429,046
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $484.9K · FY2005–18$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,429,046 · 7
By mechanism
R01$2,538,322 · 3
K02$306,545 · 1
P50$298,168 · 2
R21$286,011 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Scott W Woods$46,801,415
- Philip Corlett$6,502,664
- Joseph F. Cubells$7,878,696
- Daniel H Mathalon$8,369,757
- Albert R Powers$12,336,008
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectSmoking CessationHuman Therapy EvaluationUrinalysisSchizophreniaClinical ResearchBehavioral /Social Science Research TagDrug Abuse ChemotherapyClinical TrialsDrug WithdrawalQuestionnairesComorbidityLongitudinal Human StudyCounselingCravingTobacco AbusePatient Oriented ResearchBupropionSmokingNeuropsychological TestsAntipsychotic AgentsNicotineNicotine ReplacementCatecholamines
Grant awards (21)
Effects of rTMS on Cannabis Use and Cognitive Outcomes in Schizophrenia$130,374
R21 · FY2018 · DA · contact PI
Effects of rTMS on Cannabis Use and Cognitive Outcomes in Schizophrenia$155,637
R21 · FY2017 · DA · contact PI
Selegiline for Smoking Cessation$349,648
R01 · FY2006 · DA · contact PI
Translational Studies on Smoking in Schizophrenia$52,853
K02 · FY2006 · DA · contact PI
Selegiline for Smoking Cessation$358,063
R01 · FY2005 · DA
Translational Studies on Smoking in Schizophrenia$126,846
K02 · FY2005 · DA
Selegiline for Smoking Cessation$356,015
R01 · FY2004 · DA
Optimizing Treatment for Schizophrenic Smokers$211,950
R01 · FY2004 · DA
Translational Studies on Smoking in Schizophrenia$126,846
K02 · FY2004 · DA
Optimizing Treatment for Schizophrenic Smokers$211,950
R01 · FY2003 · DA
Nicotinic Receptors and Cog Function in Schizophrenia$211,331
R01 · FY2003 · DA
Optimizing Treatment for Schizophrenic Smokers$211,950
R01 · FY2002 · DA
Nicotinic Receptors and Cog Function in Schizophrenia$211,744
R01 · FY2002 · DA
PILOT STUDY--SELEGILINE FOR SMOKING CESSATION$0
P50 · FY2002 · DA
GABAERGIC &GLUTAMATERGIC AGENTS--COCAINE USE IN METHADONE MAINTENANCE$0
P50 · FY2002 · DA
Optimizing Treatment for Schizophrenic Smokers$211,950
R01 · FY2001 · DA
Nicotinic Receptors and Cog Function in Schizophrenia$203,721
R01 · FY2001 · DA
PILOT STUDY--SELEGILINE FOR SMOKING CESSATION$0
P50 · FY2001 · DA
GABAERGIC &GLUTAMATERGIC AGENTS--COCAINE USE IN METHADONE MAINTENANCE$0
P50 · FY2001 · DA
GABAERGIC &GLUTAMATERGIC AGENTS--COCAINE USE IN METHADONE MAINTENANCE$160,750
P50 · FY2000 · DA
PILOT STUDY--SELEGILINE FOR SMOKING CESSATION$137,418
P50 · FY2000 · DA